Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + carboplatin + metformin + paclitaxel
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination therapy consisting of bevacizumab (an anti-angiogenic monoclonal antibody), carboplatin (a platinum-based chemotherapy agent), metformin (an antidiabetic medication with potential anticancer properties), and paclitaxel (a taxane chemotherapy agent). This combination has been studied primarily for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC).
02
Targets
MicrotubuleVEGFA (Vascular endothelial growth factor A)AMPK (Adenosine monophosphate–activated protein kinase)
Beyond the preview
Go deeper on bevacizumab + carboplatin + metformin + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + carboplatin + metformin + paclitaxel.